COMP <GO>
MDT vs LLY // 10Y YIELD & FRED MACRO BETA
Medtronic plc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MDT 5
— LLY 9
▲ 10Y YIELD & FRED MACRO BETA LEADER: MDT
LAST: $96.54 (-0.59%) • MKT CAP: $124.22B
macro-sensitivity
0.91
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDT VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDT | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.00% | 83.64% | -18.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 32.36% | -24.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.4x | 36.4x | -19.02 | MDT | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 2.30% | +2.07 | MDT | /fcf-yield <GO> |
| Operating Margin | 17.80% | 40.21% | -22.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 31.90% | -31.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 8.40% | 45.51% | -37.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.93% | 0.49% | +2.44 | MDT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.08 | 9.29 | -6.21 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.77% | -0.17 | MDT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.5 | 77.9 | -17.34 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.91 | 0.51 | +0.40 | MDT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 26.3x | +113.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $124.22B | $1.33T | -$1.21T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDT REV | LLY REV | MDT GROSS % | LLY GROSS % | MDT FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.36B | $65.18B | 65.0% | 83.0% | $5.43B | $16.81B |
| FY 2024 | $33.54B | $45.04B | 65.3% | 81.3% | $5.18B | $8.82B |
| FY 2023 | $32.36B | $34.12B | 44.0% | 79.3% | $5.33B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDT // BETA 0.91
LLY // BETA 0.51